Hepatic immune cell environment in colorectal liver metastasis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031112

Enrollment

100

Registered

2023-01-23

Start date

2023-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C78.7

Interventions

Group 1: Patients with colorectal liver metastases

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female patients undergoing liver surgery for colorectal liver metastases 2. Age = 18 years 3. Informed consent for study participation 4. Available preoperative cross-sectional imaging for sarcopenia measurement

Exclusion criteria

Exclusion criteria: 1. Any factors compromising the ability of the patient to cooperate and follow study protocol (e.g. impaired cognitive function or active drug abuse)

Design outcomes

Primary

Measure	Time frame
Quantity, quality and activation status of hepatic immune cells	—

Secondary

Measure	Time frame
Sarcopenia in patients with colorectal liver metastases	—

Countries

Germany

Contacts

Public ContactUlf Peter Neumann

Klinik für Allg., Viszeral- und Transplantationschirurgie, Uniklinik RWTH Aachen

chirurgie@ukaachen.de+49 241 80 89500

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026